• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与转甲状腺素蛋白 Ala97Ser 相关的遗传性转甲状腺素蛋白淀粉样变性的心脏表现和预后意义。

Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser.

机构信息

Department of Neurology, National Taiwan University Hospital, Taiwan; National Taiwan University Hospital, Jin-Shan Branch, Taiwan.

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Division of Cardiology, Heart Center, Cheng- Hsin General Hospital, Taipei, Taiwan.

出版信息

J Formos Med Assoc. 2020 Mar;119(3):693-700. doi: 10.1016/j.jfma.2019.08.027. Epub 2019 Sep 11.

DOI:10.1016/j.jfma.2019.08.027
PMID:31521469
Abstract

BACKGROUND

The cardiac manifestations of late-onset hereditary transthyretin amyloidosis with p.A97S variant have not been extensively studied, and the prognostic factors remain unclear.

METHODS

The clinical profile, echocardiography, and ECG of patients diagnosed with ATTR p.A97S polyneuropathy between 2000 and 2016 were retrospectively collected. 67 patients with ATTR p.A97S were collected.

RESULTS

A total of 82% of patients met the criteria for left ventricular (LV) hypertrophy. Reduced global longitudinal strain (GLS) was noted in 42.1% of patients, and 14% of patients had a relative apical sparing pattern. A low voltage pattern in the ECG was observed in 31.3% of patients, while 64.2% presented with a pseudoinfarction pattern. End-systolic LV inner dimension (HR: 2.25 (95% CI: 1.01-5.01), p = 0.048), reduced GLS (HR: 5.26 (1.08-25.0), p = 0.039), relative apical longitudinal strain (RALS>1, HR: 8.57 (1.69-43.3), p = 0.009), increased E/A ratio (HR: 6.51 (1.17-36.4), p = 0.033), and increased QRS duration (HR: 1.02 (1.00-1.04), p = 0.05) were correlated with reduced survival in univariate analysis. Multivariate analysis revealed reduced RALS was significantly correlated with reduced survival (HR: 13.00 (1.81-93.45), p = 0.011).

CONCLUSION

Our findings reveal that ATTR p.A97S is a cardiomyopathy as well as a polyneuropathic syndrome. Routine use of more contemporary echocardiographic techniques are recommended to identify cardiac amyloidosis and provide prognostic information.

摘要

背景

迟发性遗传性转甲状腺素淀粉样变性伴 p.A97S 变异的心脏表现尚未得到广泛研究,其预后因素仍不清楚。

方法

回顾性收集 2000 年至 2016 年间诊断为 ATTR p.A97S 多发性神经病的患者的临床特征、超声心动图和心电图。共收集了 67 例 ATTR p.A97S 患者。

结果

82%的患者符合左心室(LV)肥厚标准。42.1%的患者存在整体纵向应变(GLS)降低,14%的患者存在相对心尖保留模式。31.3%的患者心电图出现低电压模式,64.2%的患者表现为假性梗死模式。LV 收缩末期内径(HR:2.25(95%CI:1.01-5.01),p=0.048)、GLS 降低(HR:5.26(1.08-25.0),p=0.039)、相对心尖纵向应变(RALS>1,HR:8.57(1.69-43.3),p=0.009)、E/A 比值升高(HR:6.51(1.17-36.4),p=0.033)和 QRS 持续时间延长(HR:1.02(1.00-1.04),p=0.05)与单因素分析中的生存时间降低相关。多因素分析显示,RALS 降低与生存时间降低显著相关(HR:13.00(1.81-93.45),p=0.011)。

结论

我们的研究结果表明,ATTR p.A97S 既是一种心肌病,也是一种多发性神经病综合征。建议常规使用更现代的超声心动图技术来识别心脏淀粉样变性并提供预后信息。

相似文献

1
Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser.与转甲状腺素蛋白 Ala97Ser 相关的遗传性转甲状腺素蛋白淀粉样变性的心脏表现和预后意义。
J Formos Med Assoc. 2020 Mar;119(3):693-700. doi: 10.1016/j.jfma.2019.08.027. Epub 2019 Sep 11.
2
Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.(99m)Tc-DPD 闪烁显像在遗传性转甲状腺素蛋白相关心脏淀粉样变性的诊断和预后中的作用。
JACC Cardiovasc Imaging. 2011 Jun;4(6):659-70. doi: 10.1016/j.jcmg.2011.03.016.
3
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.原因不明的左心室壁增厚患者的转甲状腺素蛋白淀粉样心肌病。
Int J Cardiovasc Imaging. 2024 Aug;40(8):1693-1703. doi: 10.1007/s10554-024-03158-z. Epub 2024 Jun 10.
4
Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis.他法米地斯可改善A97S转甲状腺素蛋白心脏淀粉样变性患者的心肌纵向应变。
Ther Adv Chronic Dis. 2024 Jan 11;15:20406223231222828. doi: 10.1177/20406223231222828. eCollection 2024.
5
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.与Pro24Ser转甲状腺素蛋白突变相关的遗传性心脏淀粉样变性:一例报告
J Med Case Rep. 2018 Dec 16;12(1):370. doi: 10.1186/s13256-018-1931-5.
6
Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.他法米替尼可降低 Ala97Ser 遗传性转甲状腺素蛋白心肌病患者的心脏淀粉样变性沉积:一项为期 12 个月的随访队列研究。
Orphanet J Rare Dis. 2023 Sep 13;18(1):289. doi: 10.1186/s13023-023-02824-0.
7
Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.转甲状腺素蛋白 Tyr78Phe 突变致淀粉样心肌病。
J Cardiovasc Transl Res. 2019 Dec;12(6):514-516. doi: 10.1007/s12265-018-9859-0. Epub 2019 Jan 2.
8
Hereditary Transthyretin Amyloidosis- Clinical and Genetic Characteristics of a Multiracial South-East Asian Cohort in Singapore.遗传性转甲状腺素蛋白淀粉样变性症-新加坡多民族东南亚队列的临床和遗传特征。
J Neuromuscul Dis. 2021;8(4):723-733. doi: 10.3233/JND-210656.
9
Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis.波兰人心血管甲状腺素运载蛋白淀粉样变性患者的转甲状腺素蛋白基因突变谱及临床特征。
Cardiol J. 2022;29(6):985-993. doi: 10.5603/CJ.a2020.0104. Epub 2020 Aug 13.
10
Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.转甲状腺素蛋白心脏淀粉样变中焦磷酸盐摄取的区域差异及其对死亡率的影响。
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):234-242. doi: 10.1016/j.jcmg.2017.06.020. Epub 2017 Oct 5.

引用本文的文献

1
Real-World Characteristics and Treatment Patterns of Patients With Transthyretin Amyloid Cardiomyopathy: Protocol for a Multicountry Disease Registry Study.转甲状腺素蛋白淀粉样变心肌病患者的真实世界特征与治疗模式:一项多国疾病登记研究方案
JMIR Res Protoc. 2025 Jun 6;14:e71314. doi: 10.2196/71314.
2
Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.他法米替尼可降低 Ala97Ser 遗传性转甲状腺素蛋白心肌病患者的心脏淀粉样变性沉积:一项为期 12 个月的随访队列研究。
Orphanet J Rare Dis. 2023 Sep 13;18(1):289. doi: 10.1186/s13023-023-02824-0.
3
Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study.
他法米地斯治疗Ala97Ser遗传性转甲状腺素蛋白心脏淀粉样变性患者的疗效:一项为期6个月的随访研究。
Acta Cardiol Sin. 2023 Jul;39(4):619-627. doi: 10.6515/ACS.202307_39(4).20221116A.
4
The Hidden Heart Disease: Shedding Light on Cardiac Amyloidosis.隐匿性心脏病:揭示心脏淀粉样变性
Acta Cardiol Sin. 2023 Jul;39(4):544-545. doi: 10.6515/ACS.202307_39(4).20230526A.
5
2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.台湾心脏病学会2023年心脏淀粉样变诊断与治疗专家共识
Acta Cardiol Sin. 2023 Jul;39(4):511-543. doi: 10.6515/ACS.202307_39(4).20230610A.
6
Natural history and survival rate of familial amyloidosis with polyneuropathy: A nationwide databank.家族性淀粉样多发性神经病的自然病史和生存率:全国数据库。
Ann Clin Transl Neurol. 2023 May;10(5):779-786. doi: 10.1002/acn3.51765. Epub 2023 Apr 12.
7
A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser.转甲状腺素蛋白 Ala97Ser 四聚体不稳定和聚集的分子基础。
Protein Sci. 2023 Apr;32(4):e4610. doi: 10.1002/pro.4610.
8
Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia.亚洲诊断和监测转甲状腺素蛋白淀粉样心肌病患者的临床建议。
Clin Cardiol. 2022 Sep;45(9):898-907. doi: 10.1002/clc.23882. Epub 2022 Jul 6.
9
Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function.转甲状腺素蛋白淀粉样心肌病:转甲状腺素蛋白淀粉样物质在心肌中的沉积对心脏形态和功能的影响。
J Pers Med. 2022 May 13;12(5):792. doi: 10.3390/jpm12050792.
10
Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders.RNA疗法及其载体治疗单基因神经疾病的最新进展
Biomedicines. 2022 Jan 12;10(1):158. doi: 10.3390/biomedicines10010158.